Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

Overview of attention for article published in OncoTargets and therapy, November 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

video: 1 YouTube creator

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X YouTube Dimensions citations

So far, Altmetric has seen 1 X post from an account with 1,965 followers.

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the #lung #respiratory https://t.co/Kq30Kkk4ZI https://t.co/mtUlrAMrWb

Reply Repost Favourite